Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
$16.11
-0.4300 ( -2.60% ) 157.3K
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Market Data
Open
$16.11
Previous close
$16.54
Volume
157.3K
Market cap
$342.05M
Day range
$15.75 - $16.66
52 week range
$8.08 - $20.04
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 14, 2024 |
10-q | Quarterly Reports | 60 | Feb 08, 2024 |
8-k | 8K-related | 14 | Feb 07, 2024 |
def | Proxies and info statements | 63 | Jan 26, 2024 |
ars | Annual reports | 1 | Jan 26, 2024 |
8-k | 8K-related | 12 | Dec 26, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 06, 2023 |
4 | Insider transactions | 1 | Dec 06, 2023 |
4 | Insider transactions | 1 | Dec 06, 2023 |